The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

The U.S. FDA has approved a prefilled syringe presentation of GSK plc’s SHINGRIX for the prevention of shingles.

The FDA has approved a prefilled syringe option of Shingrix which will streamline administration of GSK’s herpes zoster ...